Kornimate/medical-research-clean huggingface dataset:
tap dance for adults with lower limb amputation

Conditions: Amputation; Traumatic, Leg, Lower

Summary: the goal of this study is to determine whether it is possible for people with lower limb amputation (lla) to perform adapted tap dance, whether an adapted tap dance program would be enjoyable, and whether it may improve balance and balance confidence. there is a lack of research investigating therapeutic interventions for people with lower limb amputation (lla). tap dance encourages balance and novel movements of the limbs, while providing auditory feedback from the feet that provide information about the foot's contact with the ground, which may help prosthesis users gain a better ability to understand where their prosthetic foot is in space. as with most forms of dance, tap is usually taught and practiced in a group setting, which encourages community involvement. it has been shown to be safer than many forms of dance due to low impact forces. it also, as a genre, can incorporate canes, chairs and partner work, providing the ability to modify steps/moves when required so that they remain practical, achievable and safe for people with mobility limitations, while still enabling participation. it therefore may be an accessible dance medium to help improve balance, balance confidence, and build community for people with lla. participants will be asked to: * come to 1 hour dance classes, once per week, for 8 weeks. * do mobility tests before and after the program * complete questionnaires before, during and after the program. the total time for participation is approximately 8-10 weeks.


Eligibility criteria:
inclusion criteria: * unilateral or bilateral lower limb amputation at ankle level or above * fitted with a walking prosthesis, used regularly for walking in the home and the community * good socket fit * able to stand or walk for 2 minutes at a time with or without an assistive device * willing to travel to the university of nevada las vegas for tap classes once a week for 8 weeks, and for two testing sessions * able to complete all required outcome measures * able to understand written and spoken english exclusion criteria: * leg/foot ulcer/sore or other conditions that cause pain during weight-bearing * cardiovascular, respiratory or other critical health conditions that preclude moderate physical activity
prevention of imt progression in ischemic stroke patients with high risk of cerebral hemorrhage-imt study

Conditions: Brain Ischemia; Intracranial Hemorrhages

Summary: through this study, the investigators are to prove that cilostazol effectively prevent progression of intima-medial thickness in ischemic stroke patients with high risk of cerebral hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side effects. the primary hypothesis of this study is; cilostazol alone or with probucol will reduce the progression of intima-medial thickness compared to aspirin in the ischemic stroke patients with symptomatic or asymptomatic old cerebral hemorrhage.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ischemic stroke within 120 days * adult aged 20 years or older * high risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging evidence of previous intracranial hemorrhage) * informed consent exclusion criteria: * clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks * bleeding tendency * pregnant or breast-feeding woman * hemorrhagic stroke within 6 months * patient who was taking antithrombotic medication other than aspirin and does not agree to change the previous medication * severe cardiovascular disease such as cardiomyopathy or congestive heart failure * life expectancy less than one year * contraindication to long term aspirin use * enrolled in other clinical trial within 30 days

Keywords: ischemic stroke intracranial hemorrhage cilostazol probucol intima media thickness
lactobacillus reuteri versus herbal drop in the treatment of infantile colic: a prospective study

Conditions: Crying

Summary: the aim was to test the hypothesis that oral administration of lactobacillus reuteri in a prospective randomized controlled study would improve symptoms of infantile colic.

infantile colic ıs one of the most common problems within the first 3 months of life, affecting as many as 3% to 28% of newborn children. it consists of a behavioral syndrome characterized by paroxysmal, excessive, inconsolable crying without identifiable cause. lactobacillus reuteri, one of the few endogenous lactobacillus species in the human gastrointestinal tract, has been used safely for many years as a probiotic dietary supplement in adults, and recent data demonstrated safety after long-term dietary supplementation for newborn infants. the positive effects of this probiotic on intestinal disorders such as constipation and diarrhea and in protection from infection,as well as its capacity to modulate immune responses. the aim was to test the hypothesis that oral administration of lactobacillus reuteri in a prospective randomized controlled study would improve symptoms of infantile colic.

Eligibility criteria:
inclusion criteria: * infants three weeks to three months * infants with colic three hours of crying on three days in the week * infants feeding with breast milk * infants weighing 2500 to 4000 gram exclusion criteria: * chronic illness * gastrointestinal disorders * infants received either antibiotics or probiotics in the previous week

Keywords: probiotic infantile colic
is covid-19 transmitted through human milk? implications for breastfeeding and human milk banking-study 1a

Conditions: SARS-CoV2; Breastmilk

Summary: the canadian paediatric society recommends breastfeeding during covid-19 infection. human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants. the impact of a pandemic on breastfeeding is unknown. this study seeks to address this public health issue. breastmilk will be collected from mothers positive for covid-19. samples will be analyzed for the covid-19 virus specific nucleic acid and antibody in real-time and results will be immediately disseminated to relevant organizations to inform local, national and international guidelines surrounding breastfeeding to protect the health of infants.


Eligibility criteria:
inclusion criteria: * current covid-19 positive status or covid-19 positive status during pregnancy * intent to breastfeed or currently breastfeeding exclusion criteria: - none
prophylactic nepafenac and ketorolac versus placebo in patients undergoing cataract surgery

Conditions: Macular Edema

Summary: assess prophylactic efficacy of topical non-steroidal anti-inflammatory drops in preventing macular edema. patient undergoing uncomplicated cataract surgery will be enrolled and randomized to nepafenac, ketorolac, or placebo. follow-up will occur at 1 month with ocular coherence tomography (oct).


Eligibility criteria:
inclusion criteria: * ability to give informed consent * age 18 years and older exclusion criteria: * any pre-existing retinal disease (e.g., diabetic retinopathy, vein occlusion, exudative macular degeneration, etc.) * previous uveitis * previous intraocular surgery * allergy or hypersensitivity to nsaids * complicated cataract surgery

Keywords: post-cataract surgery macular edema
the effectiveness of peripheral magnetic stimulation in men with lower urinary tract symptoms

Conditions: Bladder Hypersensitivity

Summary: the main hypothesis of this study is that peripheral magnetic neuromodulation can correct the symptoms of lower urinary tract in men. we assume that under the influence of t peripheral magnetic stimulation, both the subjective state of patients assessed by standardized questionnaires and a urination diary, as well as the objective parameters, assessed by non-invasive urodynamic studies, will be improved. this study will use standard protocols built into the btl emsella magnetic stimulator.

the aim of the study is to test the hypothesis that the use of the peripheral magnetic stimulation in men with lower urinary tract symptoms will help to reduce subjective and objective clinical symptoms and improve the quality of life of patients.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years; 2. signed informed consent; 3. the presence of lower urinary tract symptoms: urinary frequency, nocturia, urgency; feeling of incomplete bladder, weak urine stream. exclusion criteria: 1. the patient, who have been implanted devices that control physiological functions (a pacemaker, a device for deep brain stimulation and chronic epidural brain stimulation, a cochlear implant). 2. convulsive attacks in the anamnesis; 3. taking medications that may trigger the risk of seizures; 4. the presence in the patient's body of metal elements or objects made with the use of ferromagnets (joint prostheses, eye prostheses, tattoos made using metal ink, surgical clips, staples and other metal suture materials, etc.) 5. chronic cardiovascular and cerebrovascular diseases in the stage of decompensation or recent acute conditions (myocardial infarction, brain stroke, etc.) 6. the presence of infravesical obstruction in men, determined by uroflowmetry (obstructive urination curve according to the liverpool nomogram); 7. the postvoid residual volume (more than 50 ml); 8. the concentration of prostate specific antigen (psa) in the blood is more than 4.0 ng / ml; 9. the presence of urinary tract infection; 10. a history of cancer of the pelvic floor organs;
international registry for asd closure by using the occlutech®flex ii device in more than 2000 patients

Conditions: Atrial Septal Defect

Summary: the irfacode ii study will evaluate the performance and safety of the occlutech® flex ii device in patients with closure of secundum atrial septal defects (asd ii).

introduction: interventional asd closure is generally a safe procedure with only a small amount of severe side effects including mainly erosion of the atrial wall, embolizations and arrhythmias. the irfacode study has shown excellent results in patients with various generations of the occlutech devices. irfacode ii study will evaluate the performance and safety of the occlutech® flex ii device in patients with closure of secundum atrial septal defects (asd ii). methods: the irfacode ii study is a retrospective, non-randomized open access study for centres with a minimum of about 50 patients to evaluate the safety and side effects of asd closure with this device. a minimum of 2000 patients that have an asd ii closed with this device until 31. june 2016 will be enrolled, the follow-up will be until 31. june 2017. primary outcome measures for safety are the amount of erosions over a minimum follow-up time of 12 months. primary outcome measures for device performance will include the success of complete asd closure. secondary outcome measures for safety will include the technique of implantation, the success rate in anatomically difficult asds, the incidence of arrhythmias (av block, atrial fibrillation or flutter), device embolization, embolic events or migraine. a subgroup analysis according to patients age and anatomy of the defect will be performed. outlook: the irfacode ii study is the first trial intended to detect the actual incidence of erosion after asd closure using the flex ii device. although the trial is primarily designed to study the safety and device performance, the incidence of other potential side effects will be also evaluated.

Eligibility criteria:
inclusion criteria: asd for device closure - exclusion criteria: * life expectancy \< 12 months * participating in another study

Keywords: irfacode ii, asd closure, asd device, erosion, arrhythmia
study of the physical and emotional needs of parents caring for children receiving chemotherapy for acute lymphoblastic leukemia

Conditions: Leukemia

Summary: rationale: studying the physical and emotional needs of parents who are caring for children receiving chemotherapy for cancer may help doctors plan effective treatments for the patient that allow for improved quality of life of the patient's family. purpose: this clinical trial is studying the different physical and emotional needs of parents whose children are undergoing chemotherapy for acute lymphoblastic leukemia either in an outpatient clinic or in the hospital.

objectives: * compare the caregiving demands reported by parents of children with acute lymphoblastic leukemia receiving methotrexate on 2 different infusion schedules (inpatient care vs outpatient care). * compare the change in caregiving demands on these parents over time, in terms of physical and emotional care, the need to make family arrangements, the need to communicate about the child's care, the need to gather information about the child's health status, and the effect on family well-being. outline: participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment. projected accrual: a total of 164 participants will be accrued for this study within 0.8 years.

Eligibility criteria:
disease characteristics: * parent or legal guardian who is the primary caregiver of a patient enrolled on cog-p9904 or cog-p9905 protocol * patient has not yet received week 13 of therapy patient characteristics: age * not specified performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * able to understand english prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: psychosocial effects of cancer and its treatment childhood acute lymphoblastic leukemia
genetics of ischemic cardiomyopathy

Conditions: Ischemic Cardiomyopathy

Summary: background:ischemic heart disease is one of the heaviest health-related burdens worldwide.we aimed to identify the common hub mrna and pathways that are involved in pathological progression of ischemic cardiomyopathy. methods: to explore potential differentially expressed genes (degs) of all ischemic heart disease stages, we used chipster and geo2r tools to analyze of retrieved eight high throughput rna datasets obtained from geo database. gene ontology functional annotation and pathways enrichment analyses were used to obtain the common functional enriched degs which were visualized in protein-protein interactions (ppi) network to explore the hub mrna according to the interaction scores. validation qrt-pcr was carried out for blood and cardiac biopsies compared with controls to validate the determined four hub mrnas and subsequently reviewed inside comprehensive published meta-analysis database. the validated mrnas were visualized in two interaction modules. finally screening of approved drugs was applied.


Eligibility criteria:
inclusion criteria the enrolled patients aged 20-80 years with stable coronary artery disease undergoing elective pci or patients with unstable angina or myocardial infarction undergoing rescue pci and admitted to the cardiology hospital (asyut university, asyut, egypt) were recruited in this study. exclusion criteria patients with dilated cardiomyopathy were execluded from this study.

Keywords: ischemic cardiomyopathy qrt-pcr
observational usage study of faslodex in patients suffering from initial breast cancer in france

Conditions: Breast Cancer

Summary: the purpose of this study is to describe the way faslodex is used in france, in patients suffering from initial breast cancer, that is to evaluate faslodex treatment duration and to determine patients profile


Eligibility criteria:
inclusion criteria: * patients suffering from initial breast cancer, treated with faslodex, treatment which was stopped during 2007

Keywords: breast cancer fulvestrant longitudinal study france
adapting single sessions interventions for type 1 diabetes

Conditions: Type 1 Diabetes (T1D)

Summary: the goal of this clinical trial is to learn if implementing a single-session depression intervention for youth with type 1 diabetes (t1d) is feasible and acceptable to patients. can help improve mood and health outcomes. it will also learn about the initial efficacy of the intervention. the main questions it aims to answer are: 1. is a single-session depression intervention for youth with t1d feasible to recruit and implement? 2. is a single-session depression intervention for youth with t1d acceptable to patients (i.e., do they find it helpful)? 3. does a single-session depression intervention for youth with t1d lead to improvements in low mood? researchers will compare a single-session depression intervention for youth with to a education control to see if a single-session depression intervention works to improve depressive symptoms. participants will: * participate in a single-session depression intervention * complete questionnaires and provide a sample for a1c at a baseline, 3-month, and 6-month visit * complete daily questionnaires once a day for two weeks before and after the single-session depression intervention


Eligibility criteria:
inclusion criteria: * child or adolescent age between 11-18 years, inclusive * physician confirmed t1d diagnosis of at least 6 months duration prior to study enrollment * positive depression screening score of \>5 on the phq-9 in the last year * not currently engaged in outpatient mental healthcare * english fluency exclusion criteria: * another systemic chronic medical illness except for celiac disease, autoimmune thyroiditis, microalbuminuria, hypertension, or well-managed asthma * any score of 1, 2, or 3 on item 9 (indicating suicidal ideation) of the phq-9 in the last year.

Keywords: type 1 diabetes adolescents depression
pazopanib and paclitaxel for non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: lung cancer is the leading cause of cancer worldwide with approximately 1.2 million new cases each year. non-small cell lung cancer (nsclc) accounts for greater than 80% of all lung carcinomas in western countries. surgical resection is the treatment of choice for patients with early stage disease (stage i and ii), but at least 50% of these patients will relapse locally and/or develop distant metastases. furthermore, 70% of patients with nsclc are non-resectable at the time of their diagnosis due to either locally advanced or metastatic disease. the long-term prognosis for patients with nsclc remains poor with the overall 5-year survival rate less than 15%. the low survival rate may be attributed to the high incidence of unresectable disease at presentation and the inability of systemic therapy to cure metastatic disease. there is a clear need for improvement in the treatment of nsclc.

the primary objective of this study is to evaluate the objective response rate of pazopanib in combination with paclitaxel in the treatment of subjects with advanced nsclc. tumor response will be assessed according to the response evaluation criteria in solid tumors (recist) criteria (version 1.1). a subject is defined as a responder if he/she sustains a complete response (cr) or a partial response (pr) for at least 4 weeks at any time during treatment. a subject without a post-baseline assessment of response will be considered a non-responder. a secondary objective of this study is to evaluate the safety and tolerability of pazopanib in combination with paclitaxel in the treatment of subjects with advanced nsclc. safety and tolerability endpoints will consist of the evaluation of adverse events (aes), exposure, withdrawals due to aes, dose reductions or interruptions, and changes from baseline in vital signs and clinical laboratory parameters.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of stage iiib (with confirmed malignant pleural effusion) or stage iv nsclc. * eastern cooperative oncology group (ecog) performance status of 0-2 * no prior systemic first-line therapy for stage iiib/iv nsclc with chemotherapy or any other biologic therapy. prior surgery and/or localized irradiation for nsclc are permitted. palliative radiation therapy must have ended 14 days prior to first dose of pazopanib. subject with recurrence after previous nsclc that has been treated with surgery with or without adjuvant chemotherapy/radiation for curative intent are eligible, provided 12 months have passed since this treatment ended. exclusion criteria: * appropriate for doublet therapy as first line therapy. at discretion of investigator.

Keywords: non-small cell lung cancer pazopanib stage iiib/iv non small cell lung cancer
hemostatic textile to control bleeding at donor graft sites

Conditions: Wounds

Summary: the rationale underlying the study is that donor site bleeding is common and often problematic when presenting to the burn surgeon or staff. frequently, gauze wound dressings are not sufficiently hemostatic to control a donor site bleed thereby leading to administration of vasoconstrictive agents and repeated application of wound dressing/pressure. the hemostatic textile stasilon™ has proven superior to gauze in reducing bleeding from anesthetized pigs undergoing standardized surgically-induced trauma. also, observational case reports have noted cessation of bleeding in a limited number of human patients with difficult to control bleeds.


Eligibility criteria:
inclusion criteria: * \>/= 18 years old * burn injury requiring allografting from donor site exclusion criteria: * \< 18 years * unable to give consent due to mental or emotional instability

Keywords: allografting